Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical (LFCR) Revenue: 2009-2025

Historic Revenue for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $36.4 million.

  • Lifecore Biomedical's Revenue fell 3.81% to $36.4 million in Q2 2025 from the same period last year, while for May 2025 it was $128.9 million, marking a year-over-year increase of 0.47%. This contributed to the annual value of $128.9 million for FY2025, which is 0.47% up from last year.
  • According to the latest figures from Q2 2025, Lifecore Biomedical's Revenue is $36.4 million, which was up 3.67% from $35.2 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical's Revenue ranged from a high of $44.9 million in Q2 2021 and a low of $21.9 million during Q4 2022.
  • For the 3-year period, Lifecore Biomedical's Revenue averaged around $31.5 million, with its median value being $31.9 million (2023).
  • Its Revenue has fluctuated over the past 5 years, first crashed by 81.82% in 2021, then skyrocketed by 37.90% in 2023.
  • Lifecore Biomedical's Revenue (Quarterly) stood at $25.6 million in 2021, then declined by 14.60% to $21.9 million in 2022, then soared by 37.90% to $30.1 million in 2023, then rose by 8.01% to $32.6 million in 2024, then decreased by 3.81% to $36.4 million in 2025.
  • Its last three reported values are $36.4 million in Q2 2025, $35.2 million for Q1 2025, and $32.6 million during Q4 2024.